1735TiP NETTER-3: A phase III study of [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, grade 1 and grade 2 (Ki-67<10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden | Publicación